on Xenetic Biosciences, Inc. (NASDAQ:XBIO)
Xenetic Biosciences' Partner Enters Clinical Study to Advance DNase Platform
Xenetic Biosciences, Inc. announced a new clinical study agreement through its partner PeriNess Ltd. The focus is on advancing the DNase I candidate, XBIO-015, for treating relapsed/refractory osteosarcoma and Ewing sarcoma. This study will be conducted at the Tel-Aviv Sourasky Medical Center.
Prof. Ronit Elhasid will lead the study, exploring the safety and efficacy of XBIO-015 combined with chemotherapy. The primary goal is to assess safety and tolerability, while secondary goals include evaluating the objective response rate and progression-free survival. Studies suggest that neutrophil extracellular traps (NETs) in tumors are linked to poor prognosis, and DNase I may counteract this effect.
James Parslow, CEO of Xenetic, emphasized the company's commitment to developing DNase combinations with various therapies across multiple cancer indications.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Xenetic Biosciences, Inc. news